Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

NCT00522990 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

48

Enrollment

INDUSTRY

Sponsor class

Stopped Recommended Phase II dose determined

Conditions

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndromes
Myelofibrosis

Interventions

DRUG: AT9283

Sponsor

Astex Pharmaceuticals, Inc.